Omid Farokhzad

Omid Farokhzad has held a number of positions in the past 18 years. From 2004 to 2020, they were a Professor of Anesthesiology at Harvard Medical School and the Director of the Lab of Nanomedicine and the Center for Nanomedicine at Brigham and Women's Hospital. In 2006, they became a Director and Founder of BIND Therapeutics, and in 2008 they were appointed Director, Chairman and Founder of Selecta Biosciences. In 2011, they became Director and Founder of Tarveda Therapeutics (formerly Blend Therapeutics). In 2019, they were appointed Director and Founder of XIRA Connect, and in 2020 they became Chair and Founder of PrognomiQ Inc. Most recently, in 2021, they were appointed Executive Chair of Dynamics Special Purpose Corp. and Chair, CEO and Founder of Seer.

Omid Farokhzad completed a Post-doctoral Fellowship in Nanomedicine and Biomaterials at the Harvard-MIT Division of Health Sciences and Technology. Omid then completed a Residency in Anesthesiology and Fellowship in Pain Medicine at Brigham and Women's Hospital. Farokhzad went on to receive their M.B.A. from the MIT Sloan School of Management, followed by an M.D. and M.A. from the Boston University School of Medicine.